Sarcoidosis
Drug research and approvals for sarcoidosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 49 studies of sarcoidosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and FDA has 0 approved and 14 open orphan designations naming it.
- Recruiting worldwide: 49
- Trials authorized in Canada: 5
- FDA orphan approvals: 0
- EU medicines: 0
- A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016)NCT07867938 · Phase 2 · Merck Sharp & Dohme LLC · starts Nov 3, 2026
- A Prospective Diagnostic Trial of Al[¹⁸F]F-NOTA-folate PET in Patients With Suspected Cardiac Sarcoidosis and Infective…NCT07814222 · Not applicable · Turku University Hospital · starts Sep 14, 2026
- Exosome-based Omic Signatures of Disease Activity in Cardiac Sarcoidosis (EXODACS)NCT07604220 · Not reported · Mayo Clinic · starts Jul 13, 2026
- Corticosteroid Tapering in SarcoidosisNCT07498842 · Not applicable · Royal Brompton & Harefield NHS Foundation Trust · starts Mar 19, 2026
- Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung DiseaseNCT07384897 · Not applicable · Université Catholique de Louvain · starts Feb 17, 2025
- Multimodal Analysis of Endomyocardial BiopsiesNCT07359690 · Not reported · University Hospital, Essen · starts Oct 27, 2025
- Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance…NCT07336394 · Not reported · Chinese Academy of Medical Sciences, Fuwai Hospital · starts Jan 1, 2010
- Repurposing Tilmanocept for Cardiac SarcoidosisNCT07159074 · Phase 2 · Duke University · starts Sep 17, 2025
- EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular DiseasesNCT07077304 · Not reported · Assistance Publique - Hôpitaux de Paris · starts Nov 19, 2025
Approved 3
- PrednisoneGlucocorticoid receptor agonist
- DexamethasoneGlucocorticoid receptor agonist
- Dexamethasone phosphoric acidGlucocorticoid receptor agonist
Phase 3 2
- InfliximabTNF-alpha inhibitor
- ThalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
Phase 2 12 of 20
- AdalimumabTNF-alpha inhibitor
- AzithromycinBacterial 70S ribosome inhibitor
- NamilumabGranulocyte-macrophage colony-stimulating factor inhibitor
- GolimumabTNF-alpha inhibitor
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- SirolimusFK506-binding protein 1A inhibitor
- RituximabB-lymphocyte antigen CD20 binding agent
- SarilumabInterleukin-6 receptor alpha subunit antagonist
- AbrocitinibTyrosine-protein kinase JAK1 inhibitor
- EthambutolArabinosyltransferase A inhibitor
- CorticotropinMelanocortin receptor 2 agonist
- AtorvastatinHMG-CoA reductase inhibitor
Phase 1 or earlier 3
- TofacitinibJanus Kinase (JAK) inhibitor
- NicotineNeuronal acetylcholine receptor; alpha4/beta2 agonist
- Tranilast
How its trials ended
279 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 59 whose ending is known, 36% met their primary endpoint, 10% missed it and 54% stopped early.
- Completed, result not reported11140%
- Ongoing7025%
- Status unknown3914%
- Met its primary endpoint218%
- Stopped: other or unclear207%
- Missed its primary endpoint62%
- Stopped: enrollment or feasibility62%
- Stopped: funding31%
- Stopped: sponsor or business decision21%
- Stopped: lack of efficacy1<1%
| Sep 15, 2026 | A phase 2 randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of tulisokibart in participants with active…Tulisokibart (MK-7240) / Prednisone | Merck & Co. (MSD) | Pending |
| Jul 7, 2026 | A phase 2/3 randomized, double-blind, placebo-controlled, dose-ranging study to investigate the safety and efficacy of oral brepocitinib in adults with…Brepocitinib (PVT-2201) | Priovant Therapeutics | Pending |
| Oct 27, 2020 | 18f-fluorodeoxyglucose in positron emission tomographyFluorodeoxyglucose (2-[18F]FLUORO-2-DEOXY-D-glucose) | Eastern Health Regional Health Authority | Ongoing |
| Jul 2, 2019 | A multicenter, randomized, double-blind, placebo-controlled study in participants with sarcoidosis-associated pulmonary hypertension (SAPH) to assess the…Selexipag | Johnson & Johnson | Closed |
| Aug 29, 2018 | Cardiac sarcoidosis multi-center randomized controlled trial (chasm cs- rct)Prednisone/ Methotrexate | Ottawa Heart Institute Research Corporation | Ongoing |
| Apr 26, 2022 | Umbilical cord mesenchymal stem cell secretomeTreatment of sarcoidosis | NRG Sciences LLC | Designated |
| Jan 5, 2022 | Human IgG1Fc- iMod domain (amino acids 2-60) of human HARS…Treatment of sarcoidosis | aTyr Pharma | Designated |
| Jul 27, 2021 | SirolimusTreatment of Sarcoidosis | AI Therapeutics | Designated |
| Nov 24, 2020 | Humanized Recombinant Anti-Tumor Necrosis Factor ?…Treatment of sarcoidosis | Xentria, Inc. | Designated |
| Jul 23, 2020 | AviptadilTreatment of sarcoidosis | Relief Therapeutics International SA | Designated |
| Jul 21, 2020 | Alidornase alfaTreatment of sarcoidosis | SarcoMed USA, Inc. | Designated |
| Jan 14, 2020 | 5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidi…Treatment of sarcoidosis | Molecure S.A. (previously OncoArendi S.A.) | Designated |
| Jun 4, 2019 | Dornase alfaTreatment of sarcoidosis | SarcoMed USA, LLC | Designated |
| Jun 13, 2016 | L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-…Treatment of sarcoidosis. | Araim Pharmaceuticals, Inc. | Designated |
| Sep 13, 2011 | L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-…Treatment of neuropathic pain in patients with sarcoidosis. | Araim Pharmaceuticals, Inc. | Designated |
| Feb 4, 2011 | ThymopentinTreatment of sarcoidosis. | Mondobiotech Laboratories AG | Designated |
| Aug 9, 2006 | Clindamycin hydrochlorideTreatment of sarcoidosis | Autoimmunity Research Foundation | Designated |
| Mar 28, 2006 | Minocycline hydrochlorideTreatment of sarcoidosis | Autoimmunity Research Foundation | Designated |
| Feb 16, 2005 | Nitric oxideDiagnosis of sarcoidosis | SensorMedics Corporation | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA